Blood Lines
viagra in women effects synopsis
bio
links
order
watch a clip
A view into the souls of HIV+ youth Produced & Directed by: Rebecca Guberman & Jennifer Jako

New updated 2015 version now available

The New York Times calls Blood Lines "a pointed, moving documentary" and "an eloquent plea for understanding"
For treatment of hepatocellular carcinoma, at least half of surveyed oncologists view a four-month improvement in overall survival or in progression-free survival over nexavar as individually sufficient to prescribe a new drug ahead of nexavar emerging small-molecule agents in renal cell carcinoma/hepatocellular carcinoma that fail to garner formulary coverage comparable to that of current therapies will have difficulty building patient share among some surveyed physicians june 26, 2012—burlington, mass. —decision resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed u. S. Oncologists prefer to use bayer healthcare/onyx pharmaceuticals’ nexavar as a front-line treatment for advanced hepatocellular carcinoma (hcc) patients, rather than reserving it for later lines, and their prescribing is aided by the 84 percent of surveyed managed care organizations (mcos) that reimburse nexavar on their commercial plans. The majority of surveyed oncologists view improvement in overall survival over that of nexavar as the greatest unmet need to be addressed by an emerging therapy for hcc. At least half of surveyed oncologists view a four-month improvement in overall survival or a four-month improvement in progression-free survival over nexavar as individually sufficient to prescribe a new drug ahead of nexavar for the treatment of hcc. However, despite a strong focus on the efficacy of nexavar, concerns about patient costs may make oncologists receptive to new therapies, if they have patient assistance programs that reduce copays. The new u. S. Physician & payer forum report entitled renal cell carcinoma and hepatocellular carcinoma: how will u. S. Payer and physician attitudes impact prescribing of small-molecule oral therapies? buy viagra online cheap free shipping canada viagra generic viagra generic buy online cheapest generic super viagra generic viagra online buy viagra online generic viagra for sale in usa order viagra online usa cost of generic viagra 100mg cheapest viagra to buy Also finds that although pfizer’s sutent dominates surveyed oncologists’ prescribing in the first-line setting for renal cell cancer (rcc), treatment of rcc in subsequent lines of therapy is highly fragmented and no single agent dominates patient share. Furthermore, 66 percent of surveyed commercial plans that reimburse for sutent cover the agent on tier 1 or 2 of their formularies. Most surveyed oncologists say overall survival benefit is the factor that most strongly influences their selection of small-molecule agents for the first- and second-line treatment of rcc. Among all the angiogenesis inhibitors approved for advanced rcc, sutent is the one with which the majority of surveyed oncologists are most familiar, and which physici.
For pricing and order information please e-mail: info@blood-lines.org or call: 503-239-0164